AR054519A1 - Moduladores no esteroides de receptor de progesterona - Google Patents
Moduladores no esteroides de receptor de progesteronaInfo
- Publication number
- AR054519A1 AR054519A1 ARP060102750A ARP060102750A AR054519A1 AR 054519 A1 AR054519 A1 AR 054519A1 AR P060102750 A ARP060102750 A AR P060102750A AR P060102750 A ARP060102750 A AR P060102750A AR 054519 A1 AR054519 A1 AR 054519A1
- Authority
- AR
- Argentina
- Prior art keywords
- nrcrd
- alkyl
- alkynyl
- alkenyl
- aryl
- Prior art date
Links
- 239000002379 progesterone receptor modulator Substances 0.000 title 1
- 229940095745 sex hormone and modulator of the genital system progesterone receptor modulator Drugs 0.000 title 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 7
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 7
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005010 perfluoroalkyl group Chemical group 0.000 abstract 3
- 150000003254 radicals Chemical class 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 241000347391 Umbrina cirrosa Species 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 150000005840 aryl radicals Chemical class 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 230000035558 fertility Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 238000002657 hormone replacement therapy Methods 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 201000007954 uterine fibroid Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Su uso para la preparacion de medicamentos y a las composiciones farmacéuticas que contienen estos compuestos. Los compuestos son apropiados para la terapia y la prevencion de enfermedades ginecologicas, como endometriosis, leiomiomas del utero, sangrados disfuncionales y dismenorrea y para el tratamiento y la prevencion de tumores hormona-dependientes y para el control de la fertilidad femenina, así como para la terapia de sustitucion hormonal. Reivindicacion 1: Compuestos de la formula general (1), caracterizado porque: R1 y R2 representan independientemente uno de otro, un átomo de hidrogeno, un grupo alquilo C1-5 lineal o no-lineal, ramificado o no-ramificado, además, junto con el átomo de C de la cadena forman un anillo con un total de 3-7 miembros; R3 representan un radical C:::C-Ra, donde: Ra es un hidrogeno o es alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-10, heterocicloalquilo, opcionalmente mono o polisustituido con K, de manera igual o diferentes o significa un arilo o heteroarilo, opcionalmente mono o polisustituido con L, de manera igual o diferente; K significa ciano, halogeno, hidroxilo, nitro, C(O)Rb, CO2Rb, -O-Rb, -S-Rb, SO2NRcRd, -C(O)-NRcRd, -OC(O)-NRcRd, -C=NORb -NRcRd o es cicloalquilo C3-10, heterocicloalquilo, opcionalmente mono o polisustituido con M, de manera igual o diferente o significa arilo o heteroarilo, opcionalmente mono o polisustituido con L; L significa alquilo C1-8, alquenilo C2-8, alquinilo C2-8, perfluoroalquilo C1-6, perfluoralcoxilo C1-6, alcoxiC1-6-alcoxiloC1-6, (CH2)p-cicloalquiloC3-10, (CH2)p-heterocicloalquilo, (CH2)pCN, (CH2)pHal, (CH2)pNO2, (CH2)p-C6-12-arilo, (CH2)p-heteroarilo, -(CH2)pPO3(Rb)2, -(CH2)pNRcRd, -(CH2) pNReCORb, - (CH2)pNReCSRb, -(CH2)pNReS(O)Rb, -(CH2)pNReS(O)2Rb, -(CH2)pNReCONRcRd, -(CH2)pNReCOORb, -(CH2)pNReC(NH)NRcRd, -(CH2)pNReCSNRcRd, -(CH2)pNReS(O)NRcRd, -(CH2)pNReS(O)2NRcRd, -(CH2)pCORb, -(CH2)pCSRb, -(CH2)pS(O)Rb, -(CH2)pS(O)(NH)Rb, -(CH2)pS(O)2Rb, - (CH2)pS(O)2NRcRd, -(CH2)pSO2ORb, -(CH2)pCO2Rb, -(CH2)pCONRcRd, -(CH2)pCSNRcRd, -(CH2)pORb, -(CH2)pSRb, -(CH2) pCRb(OH)-Re, -(CH2)p-C=NORb, -O-(CH2)n-O-, -O-(CH2)n-CH2-, -O-CH=CH- o -(CH2)n+2-, donde n = 1 o 2 y los átomos de oxígeno y/o carbono en posicion final están unidos con átomos de carbono del anillo directamente adyacentes; M es alquilo C1-6 o un grupo -CORb, CO2Rb, -O-Rb, o -NRcRd, donde Rb significa un hidrogeno o un grupo alquilo C1-6, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-10, arilo C6-12 o perfluoroalquilo C1-3; y Rc y Rd representan independientemente uno de otro un hidrogeno, alquilo C1-6, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-10, arilo C6-12, C(O)Rb o un grupo hidroxilo, donde cuando: Rc es un grupo hidroxilo, Rd solamente puede ser un hidrogeno, un alquilo C1-C6, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-10 o arilo C6-12 y viceversa; y Re representa un hidrogeno, alquilo C1-6, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-10 o arilo C6- 12; y p puede ser un numero de 0-6; o R3 representa un radical C=C-RgRh, donde: Rg y Rh representan independientemente uno de otro un hidrogeno o un alquilo C1-8, alquenilo C2-C8 o alquinilo C2-C8, opcionalmente mono o polisustituido con X, de manera igual o diferentes, donde X es un ciano, halogeno, hidroxilo, nitro, -C(O)Rb, CO2Rb, -O-Rb, -C(O)-NRcRd, - NRcRd con los significados mencionados más arriba para Rb, Rc y Rd; y R4 es un átomo de hidrogeno, un grupo metilo o etilo o un grupo alquilo C1-3 parcial o totalmente fluorado; A representa un anillo aromático mono- o bicíclico, carbocíclico o heterocíclico, que puede estar opcionalmente mono- o polisustituido con alquilo C1-8, alquenilo C2-8, alquinilo C2-8, perfluoroalquilo C1- 6, perfluoralcoxilo C1-6, alcoxiC1-6- alquiloC1-6, alcoxiC1-6-alcoxiloC1-6, (CH2)p-cicloalquiloC3-10, (CH2)p-heterocicloalquilo, (CH2)pCN, (CH2)pHal, (CH2)pNO2, (CH2)p-ariloC6-12, (CH2)p-heteroarilo; -(CH2)pPO3(Rb)2, -(CH2)pNRcRd, -(CH2)pNReCORb, - (CH2)pNReCSRb, -(CH2)pNReS(O)Rb, -(CH2)pNReS(O)2Rb, -(CH2) pNReCONRcRd, -(CH2)pNReCOORb, -(CH2)pNReC(NH)NRcRd, -(CH2)pNReCSNRcRd, -(CH2)pNReS(O)NRcRd, -(CH2)pNReS(O)2NRcRd, -(CH2) pCORb, -(CH2)pCSRb, -(CH2)pS(O)Rb, -(CH2)pS(O)(NH)Rb, -(CH2)pS(O)2Rb, - (CH2)pS(O)2NRcRd, -(CH2)pSO2ORb, -(CH2)pCO2Rb, -(CH2) pCONRcRd, -(CH2)pCSNRcRd, -(CH2)pORb, -(CH2)pSRb, -(CH2)pCRb(OH)-Rd, -(CH2)p-C=NORb, -O-(CH2)n-O-, -O-(CH2)n-CH2-, -O-CH=CH- o -(CH2)n+2-, donde n = 1 o 2 y los átomos de oxígeno y/o carbono en posicion final están unidos con átomos de carbono del anillo directamente adyacentes; o A representa un radical -CO2Rb, C(O)NRcRd, CORb; o A representa un grupo alquenilo-CR5=CR6R7, donde R5, R6 y R7 son iguales o diferentes y representan independientemente uno de otro, átomos de hidrogeno, átomos de halogeno, radicales arilo o un grupo alquilo C1-5 insustituidos o parcial o completamente fluorado; o A representa un grupo alquinilo-C:::R5, con el significado mencionado más arriba para R5; y B representa un grupo carbonilo o CH2, así como sus sales aceptables para uso farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005030292A DE102005030292A1 (de) | 2005-06-24 | 2005-06-24 | Nichtsteroidale Progesteronrezeptor-Modulatoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054519A1 true AR054519A1 (es) | 2007-06-27 |
Family
ID=37199176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102750A AR054519A1 (es) | 2005-06-24 | 2006-06-27 | Moduladores no esteroides de receptor de progesterona |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1902049A2 (es) |
| JP (1) | JP2008543910A (es) |
| KR (1) | KR20080030622A (es) |
| CN (1) | CN101248066A (es) |
| AR (1) | AR054519A1 (es) |
| AU (1) | AU2006261048A1 (es) |
| BR (1) | BRPI0611903A2 (es) |
| CA (1) | CA2611897A1 (es) |
| CR (1) | CR9598A (es) |
| DE (1) | DE102005030292A1 (es) |
| DO (1) | DOP2006000148A (es) |
| EA (1) | EA200702524A1 (es) |
| EC (1) | ECSP078044A (es) |
| GT (1) | GT200600271A (es) |
| IL (1) | IL188021A0 (es) |
| MX (1) | MX2008000072A (es) |
| NO (1) | NO20080440L (es) |
| PE (1) | PE20070125A1 (es) |
| TW (1) | TW200740778A (es) |
| UY (1) | UY29624A1 (es) |
| WO (1) | WO2006136461A2 (es) |
| ZA (1) | ZA200800690B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY30805A1 (es) * | 2006-12-21 | 2008-07-31 | Bayer Schering Pharma Ag | Moduladores no esteroides de receptores de progesterona |
| DE102007032800A1 (de) * | 2007-07-10 | 2009-01-15 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| DE102007058747A1 (de) * | 2007-12-05 | 2009-06-10 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| JP2011519916A (ja) * | 2008-07-02 | 2011-07-14 | ファーマコステック カンパニー リミテッド | アミド誘導体の製造方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19856475A1 (de) * | 1998-11-27 | 2000-05-31 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| EP1344776A1 (en) * | 2002-03-11 | 2003-09-17 | Schering Aktiengesellschaft | 5- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -phtalide and 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one derivatives with progesterone receptor modulating activity for use in fertility control, hormone replacement therapy and the treatment of gynecological disorders |
| RS20050974A (sr) * | 2003-07-01 | 2007-09-21 | Schering Aktiengesellschaft, | Heterociklično supstituisani pentanol-derivati,postupak za njihovo dobijanje i njihova primena kao supresora zapaljenja |
-
2005
- 2005-06-24 DE DE102005030292A patent/DE102005030292A1/de not_active Ceased
-
2006
- 2006-06-22 EA EA200702524A patent/EA200702524A1/ru unknown
- 2006-06-22 KR KR1020087001793A patent/KR20080030622A/ko not_active Withdrawn
- 2006-06-22 EP EP06762404A patent/EP1902049A2/en not_active Withdrawn
- 2006-06-22 BR BRPI0611903-4A patent/BRPI0611903A2/pt not_active Application Discontinuation
- 2006-06-22 CN CNA2006800308707A patent/CN101248066A/zh active Pending
- 2006-06-22 WO PCT/EP2006/006531 patent/WO2006136461A2/en not_active Ceased
- 2006-06-22 AU AU2006261048A patent/AU2006261048A1/en not_active Abandoned
- 2006-06-22 MX MX2008000072A patent/MX2008000072A/es not_active Application Discontinuation
- 2006-06-22 CA CA002611897A patent/CA2611897A1/en not_active Abandoned
- 2006-06-22 JP JP2008517444A patent/JP2008543910A/ja active Pending
- 2006-06-23 TW TW095122742A patent/TW200740778A/zh unknown
- 2006-06-26 UY UY29624A patent/UY29624A1/es not_active Application Discontinuation
- 2006-06-26 DO DO2006000148A patent/DOP2006000148A/es unknown
- 2006-06-26 PE PE2006000733A patent/PE20070125A1/es not_active Application Discontinuation
- 2006-06-27 AR ARP060102750A patent/AR054519A1/es unknown
- 2006-06-28 GT GT200600271A patent/GT200600271A/es unknown
-
2007
- 2007-12-10 IL IL188021A patent/IL188021A0/en unknown
- 2007-12-17 CR CR9598A patent/CR9598A/es not_active Application Discontinuation
- 2007-12-21 EC EC2007008044A patent/ECSP078044A/es unknown
-
2008
- 2008-01-23 ZA ZA200800690A patent/ZA200800690B/xx unknown
- 2008-01-23 NO NO20080440A patent/NO20080440L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA200702524A1 (ru) | 2008-06-30 |
| IL188021A0 (en) | 2008-03-20 |
| DOP2006000148A (es) | 2007-07-15 |
| CR9598A (es) | 2008-04-09 |
| EP1902049A2 (en) | 2008-03-26 |
| UY29624A1 (es) | 2007-01-31 |
| PE20070125A1 (es) | 2007-02-14 |
| MX2008000072A (es) | 2008-03-24 |
| KR20080030622A (ko) | 2008-04-04 |
| TW200740778A (en) | 2007-11-01 |
| ECSP078044A (es) | 2008-01-23 |
| ZA200800690B (en) | 2009-09-30 |
| DE102005030292A1 (de) | 2007-01-11 |
| GT200600271A (es) | 2007-02-05 |
| BRPI0611903A2 (pt) | 2010-10-05 |
| JP2008543910A (ja) | 2008-12-04 |
| NO20080440L (no) | 2008-03-25 |
| CN101248066A (zh) | 2008-08-20 |
| CA2611897A1 (en) | 2006-12-28 |
| AU2006261048A1 (en) | 2006-12-28 |
| WO2006136461A2 (en) | 2006-12-28 |
| WO2006136461A3 (en) | 2007-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY28157A1 (es) | Miméticos de glucocorticoides métodos para su elaboración composiciones farmacéuticas y sus usos | |
| AR074021A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| AR029740A1 (es) | Compuestos derivados de la n-(4-carbamimidoil-fenil)-glicina ,su uso , procedimiento de obtencion de los mismos, preparados farmaceuticos que los contienen y compuestos derivados de la n-(4-ciano-fenil)-glicina | |
| BRPI0518798A2 (pt) | composto, composiÇço farmacÊutica, e, mÉtodos para tratar diabete tipo ii e para tratar uma condiÇço ou distérbio | |
| EA200970868A1 (ru) | Производные плевромутилина для лечения заболеваний, опосредуемых микробами | |
| MX379814B (es) | Proceso para preparar compuestos de dihidroisoquinolinas-fenil-purinas. | |
| NI201000110A (es) | Derivados bicíclicos para usar en el tratamiento de afecciones asociadas con el receptor de andrógeno. | |
| ECSP045229A (es) | Piridinonas sustituidas como moduladores de la p38 map quinasa | |
| AR067051A1 (es) | Indazoles sustituidos, su preparacion y su utilizacion terapeutica | |
| UY32543A (es) | Análogos de isoxazol-3(2h)-ona como agentes terapéuticos | |
| ECSP10010368A (es) | Derivados de urea de tetrahidroquinoxalina, su preparación | |
| AR061642A1 (es) | Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas | |
| BR112014029868A2 (pt) | compostos, e, composição farmacêutica | |
| ES2559854T3 (es) | Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica | |
| AR054624A1 (es) | DERIVADOS DE PIRROL[2, 3 - B]PIRIDINA, UN INTERMEDIARIO PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA Y UN KIT QUE LOS COMPRENDE Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA MODULACIoN DE LA ACTIVIDAD DE LAS PROTEíNAS KINASAS., | |
| AR050186A1 (es) | Derivados de amino-piperidina, su preparacion y su aplicacion en terapeutica. | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| ECSP099216A (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR073565A1 (es) | Derivados de bencimidazol, procesos de preparacion y composiciones farmaceuticas que los contienen | |
| UY31990A (es) | Nuevos derivados | |
| ECSP109961A (es) | Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica | |
| AR054519A1 (es) | Moduladores no esteroides de receptor de progesterona | |
| AR071587A1 (es) | Compuestos heterociclicos como inhibidores de mek | |
| PE20080191A1 (es) | Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6 | |
| AR057409A1 (es) | Heterociclos oxigenados como moduladores de receptores de progesterona. composiciones farmaceuticas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |